Incyte (INCY) and partner Xencor (XNCR) have reported promising late-stage trial results for their immunotherapy Monjuvi in treating a common form of lymphoma.
The CD19-targeting monoclonal antibody demonstrated a 25% improvement in cancer-free survival when combined with other drugs in the trial.
The late-stage trial data, reported on Saturday, positions Monjuvi as a strong candidate for first-line treatment of the lymphoma type studied.
Monjuvi’s performance in the trial marks a significant step forward for both Incyte and Xencor, who jointly developed the therapy.
The drug’s CD19-targeting mechanism is central to its ability to combat lymphoma cells as part of a broader treatment combination.
First-line designation would represent a major commercial milestone for Monjuvi, expanding its use to patients at the earliest stage of treatment.
The trial results are expected to support regulatory submissions aimed at broadening the approved indications for the immunotherapy.
Incyte (INCY) has been actively building its oncology portfolio, and Monjuvi remains one of its most closely watched cancer assets.
Xencor (XNCR), which co-developed the antibody, stands to benefit from the expanded commercial opportunity if regulators approve the new indication.
The positive data reinforces growing confidence in CD19-targeting therapies as an increasingly important class of treatment within the lymphoma space.
